ToolGen Inc.

In News

ToolGen Files Patent Infringement Lawsuit Against Lonza in the Netherlands - PR Newswire

PR Newswire - Sep 08, 2025

ToolGen and BarentsKrans step up CRISPR battle against Vertex - JUVE Patent

JUVE Patent - Sep 12, 2025

Vertex, Crispr’s Casgevy Accused of Infringing New ToolGen Patent - Bloomberg Law News

Bloomberg Law News - Nov 19, 2025

ToolGen sues Vertex in US, expanding CRISPR patent licensing dispute - IAM Media

IAM Media - Nov 28, 2025

ToolGen and GenEditBio form cross-license deal for genome editing tech - Investing.com

Investing.com - Nov 24, 2025

ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com

koreabiomed.com - Apr 22, 2025

Federal Circuit Revives CRISPR-Cas9 Patent Priority Dispute - Wilson Sonsini

Wilson Sonsini - May 16, 2025

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - PR Newswire

PR Newswire - Apr 21, 2025

A South Korean Company is Fighting to Stake its Claim in the CRISPR Patent Battle - Seed World

Seed World - Dec 14, 2023

ToolGen and Vertex focus battle over CRISPR/Cas therapy Casgevy in Europe - JUVE Patent

JUVE Patent - May 08, 2025

Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - Yahoo Finance

Yahoo Finance - Apr 21, 2025

ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics - The Manila Times

The Manila Times - Nov 24, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment